logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Amgen: Positive Data from Osteoporosis Trial. Aerie Pharmaceuticals: More Data on Glaucoma Drug Safety.

Amgen (AMGN) and  UCB (Euronext Brussels: UCB) announced positive results from the BRIDGE pivotal Phase 3 placebo-controlled study evaluating the efficacy and safety of romosozumab in treating men with osteoporosis.   The study met the primary endpoint,  demonstrating a statistically significant increase...

Read More

March 22, 2016

0

Denali Therapeutics: Born with Good News in Hand.

On Dec. 12, 2017,  Denali Therapeutics (DNLI)  announced the closing of its initial public offering of 15,972,221 shares of its common stock at a price to the public of $18.00 per share. On January 5, 2018, less than one month since it...

Read More

January 5, 2018

0

Immunokinases Attract Roche to Blueprint Medicine. Spectrum Granted FDA Approval.

Immunotherapy for Cancer Blueprint Medicines Blueprint Medicines (BPMC)   entered into a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) for the discovery, development and commercialization of up to five small...

Read More

March 16, 2016

0

Merck’s Good News. Checkpoint Inhibitors’ Revenues

Checkpoint inhibitors approved for a few firms as immunotherapy for cancer are increasingly demonstrating their superiority in extending the lives of patients when given as first-line treatments. In the news,  Merck’s (MRK)  anti-PD-1 therapy, pembrolizumab (Keytruda®) in combination with pemetrexed...

Read More

January 16, 2018

0

Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

VERTEX From Europe,  Vertex (VRTX)  was informed that the European Commission has granted an extension of the Marketing Authorization for  ORKAMBI ®   (lumacaftor/ivacaftor). Orkambi is for cystic fibrosis (CF) in people with two copies of the  F508del  mutation, including...

Read More

January 11, 2018

0

Celator: Improving on AML Standard of Care Treatment. The Stock Rallied.

First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial  in high-risk Acute Myeloid Leukemia (AML)   NDA submission for VYXEOS planned for later this year   Celator Pharmaceuticals (CPXX) announced...

Read More

March 15, 2016

0

Xoma: The Considered Dead is Alive and Kicking. Gilead is Way Undervalued

The Diagnosed Dead Is Far from Dying Xoma (XOMA) : Stock rallied following report announcing an upfront payment from  Novartis , which multiplied the firm’s revenues 10 times over 2014. Novartis paid Xoma $37 million, Novo Nordisk paid $5 million...

Read More

March 11, 2016

0

Jazz Pharmaceuticals: The Expected Good News on March 31, 2016

Of the Upcoming Game-Changing Actions THE EXPECTED FDA APPROVAL OF JAZZ DRUG DEFIBROTIDE On March 31,  the   FDA is expected to decide on the approval of  Jazz Pharmaceuticals’ (JAZZ)   drug  defibrotide.  The drug is for patients with hepatic...

Read More

March 10, 2016

0

Congratulations: The FDA Approved Portola’s Anticoagulant Drug Bevyxxa (betrixaban). The Stock Rallied.

Portola (PTLA) announced that the U.S. Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban), the first anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical...

Read More

June 23, 2017

0

About Bellicum Pharmaceuticals' Product BPX-501

IMPRESSIVE RESULTS?  Bellicum Pharmaceuticals’ (BLCM) drug BPX-501 is described as a safe and effective product that can offer children with cancer and other serious diseases the opportunity to beat their intractable sicknesses. The drug enables the patients who are in...

Read More

June 27, 2017

0

  • Previous
  • 1
  • 2
  • ...
  • 27
  • 28
  • 29
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy